Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cipla
Argus Health
Queensland Health
Healthtrust
Covington

Generated: July 23, 2019

DrugPatentWatch Database Preview

Patent: 10,081,671

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,081,671
Title:Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
Abstract: This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1.times.10.sup.-9M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.
Inventor(s): Koch; Holger (San Jose, CA), Urwyler; Simon (San Jose, CA), Rudolf; Michael (San Jose, CA), Truong; Vu (Campbell, CA)
Assignee:
Application Number:15/523,190
Patent Claims:see list of patent claims

Details for Patent 10,081,671

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19 ➤ Sign Up ➤ Sign Up RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19 ➤ Sign Up ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Accenture
Daiichi Sankyo
Citi
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.